Evaluation the effects of Favipiravir in COVID-19 patients

Phase 3

Recruiting

• Conditions: COVID-19 pneumonia.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20151227025726N14
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

Laboratory confirmed COVID-19 with RT-PCR
Age over 18 years old
Oxygen saturation < 93%
Fever more than 72 hours before admission
Bilateral pulmonary infiltration

Exclusion Criteria

Chronic kidney Disease
Acute kidney Injury
Pregnancy or breastfeeding
Drug allergy history
Chronic liver disease
Mild phase of COVID-19
Critical phase of COVID-19

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.

Secondary Outcome Measures

Name	Time	Method
Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Death. Timepoint: At end of the study. Method of measurement: Medical Record.;Needs of mechanical ventilation. Timepoint: Daily. Method of measurement: Medical Record.